Verastem Oncology names Michael Bailey as CEO starting January 2027

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Verastem Oncology names Michael Bailey as CEO starting January 2027

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

October 14, 2026 6:01 AM EDT

Accomplished biopharmaceutical executive Michael P. Bailey appointed President and CEO to advance Verastems commercial business and lead pipeline asset advancement for VS-7375, a potential best-in-class investigational oral KRAS G12D (ON/OFF) inhibitor

Daniel Paterson to retire as President and CEO following a 35-year career in the biopharmaceutical industry; will remain as an advisor and member of Verastems Board of Directors

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers,... More